Belpointe Asset Management LLC Has $2.92 Million Stock Holdings in Pfizer Inc. $PFE

Belpointe Asset Management LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 120,284 shares of the biopharmaceutical company’s stock after selling 9,819 shares during the period. Belpointe Asset Management LLC’s holdings in Pfizer were worth $2,916,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Bessemer Group Inc. increased its position in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK raised its stake in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after purchasing an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer in the first quarter valued at $8,283,000. Westbourne Investments Inc. acquired a new stake in shares of Pfizer in the first quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. boosted its position in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock opened at $26.45 on Tuesday. The firm has a 50 day moving average of $24.72 and a two-hundred day moving average of $24.12. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a market capitalization of $150.38 billion, a price-to-earnings ratio of 14.07, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on PFE shares. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.